Bristol-Myers Squibb BMY Other Legacy products — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's other legacy products — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's other legacy products — total revenues?
- Bristol-Myers Squibb (BMY) reported other legacy products — total revenues of $170M in Q2 2026.
- How has Bristol-Myers Squibb's other legacy products — total revenues changed year-over-year?
- Bristol-Myers Squibb's other legacy products — total revenues decreased by 23.8% year-over-year, from $223M to $170M.
- What is the long-term trend for Bristol-Myers Squibb's other legacy products — total revenues?
- Over 3 years (2022 to 2025), Bristol-Myers Squibb's other legacy products — total revenues has grown at a -11.8% compound annual growth rate (CAGR), from $1.16B to $798M.
- What does other legacy products — total revenues mean?
- This metric represents the aggregate revenue generated from the company's portfolio of mature pharmaceutical products that have passed their peak growth phase. These products typically face generic competition or have been superseded by newer therapeutic innovations within the company's pipeline. Monitoring this revenue stream is essential for assessing the rate of decline in older assets and the company's ability to manage the transition toward newer, high-growth drug launches.